<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089387</url>
  </required_header>
  <id_info>
    <org_study_id>BT06-07</org_study_id>
    <secondary_id>2008-A01248-47</secondary_id>
    <nct_id>NCT01089387</nct_id>
  </id_info>
  <brief_title>Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction</brief_title>
  <acronym>INSTIN</acronym>
  <official_title>Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erectile dysfunction is a frequent adverse event after radical prostatectomy for prostate
      cancer.

      It is the consequence of penile vascular damage, mainly arterial insufficiency and venous
      leakage associated with fibrosis of the corpus cavernous. Apoptosis of penile cells,
      including mesenchymal cells, smooth muscle cells and endothelial is believed to play an
      important role in the pathophysiology of post prostatectomy erectile dysfunction.

      Bone marrow mononucleated cells (BMMNC) contain different cell types that may replace the
      damaged penile cells after radical prostatectomy. These are mainly: mesenchymal stem cells,
      endothelial progenitor cells and hematopoietic stem cell. Intracavernous injection of BMMNC
      may therefore find application in the treatment of post prostatectomy erectile dysfunction.

      The aims of this phase I-II study is to test the safety of autologous intracavernous BMMNC
      injection and to evaluate benefit for the patient concerning recovery of natural erection.
      Patients with penile vascular abnormality (echo-doppler) and localized prostate cancer
      (considered as cured by radical prostatectomy) will be included in this study.

      Four different doses of BMMNC will be tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have shown in a rat model of post prostatectomy erectile dysfunction that BMMNC injection
      replace apoptotic cavernous cells and restore erectile function.

      In the pig, the injection of high dose of BMMNC into the corpus cavernosus does not cause
      side effect. Moreover, the BMMNC remains at the injection site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of serious adverse event (general or local)</measure>
    <time_frame>6 months</time_frame>
    <description>Side effects envisaged: priapism, local inflammation after cell injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of natural erection, improvement of penile doppler parameters</measure>
    <time_frame>6 month</time_frame>
    <description>Evaluation of erectile recovery using validated quesitonnaires (IIEF15, EHS, UCLA-PCI)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>injection of bone marrow cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>injection of bone marrow mononucleated cells</intervention_name>
    <description>Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.</description>
    <arm_group_label>injection of bone marrow cells</arm_group_label>
    <other_name>cell therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Localized prostate cancer: PSA (Prostate Specific Antigen) prior to radical
             prostatectomy &lt; 10 ng/ml, histopathologic analysis of the prostate showing a prostate
             cancer with Gleason score ≤ 7, negative margin, absence of effraction of the prostatic
             capsule, pT1 or pT2 N0 or NX.

          -  PSA=0 ng/ml 6 months after radical prostatectomy.

          -  Normal erectile function prior to radical prostatectomy.

          -  Penile arterial insufficiency and or venous leakage (doppler) at the time of
             inclusion: PSV &lt;25 cm/sec, PSV &gt;25 cm/sec, EDV&gt;5cm/sec, RI&lt;0,75.

        Exclusion Criteria:

          -  Non localized prostate cancer.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Henri Mondor-Albert Chenevier-Centre Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94101</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radical prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

